<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>IBM offers a major opening for disease-modifying, steroid-sparing therapies. With no approved drugs, inconsistent off-label benefits and a sparse pipeline, opportunities include targeted immunotherapies, muscle-protective agents, improved diagnosis and supportive care.Dublin, Aug. 14, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/report/global-inclusion-body-myositis-drug-market?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=cv7wbr&amp;utm_campaign=2325560+-+Inclusion+Body+Myositis+Market+Report+2020-2034%3a+Epidemiology%2c+Treatment+Landscape%2c+Pipeline+and+Forecast+Across+the+7M&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="Inclusion Body Myositis - Market Insight, Epidemiology, and Market Forecast - 2034">"Inclusion Body Myositis - Market Insight, Epidemiology, and Market Forecast - 2034"</a> has been added to ResearchAndMarkets.com's offering. The "Inclusion Body Myositis (IBM) - Market Insight, Epidemiology, and Market Forecast - 2034" report provides a comprehensive analysis of the inclusion body myositis market, patient population, treatment landscape, emerging therapies and commercial opportunities across the seven major markets (7MM). Coverage includes the United States, Germany, France, Italy, Spain, the United Kingdom and Japan, with historical and forecast data spanning 2020 to 2034. Key Highlights <ul><li>Inclusion body myositis remains one of the most underserved idiopathic inflammatory myopathies, creating demand for faster, safer and steroid-sparing treatments.</li><li>There are currently no FDA-approved therapies for IBM. Clinical management may include off-label glucocorticoids, methotrexate, cyclophosphamide, azathioprine, intravenous immunoglobulin and alemtuzumab, although benefits are limited or inconsistent.</li><li>Supportive interventions, including physical and occupational therapy, fall prevention, swallowing management and assistive devices, remain central to patient care.</li><li>Several advanced IBM programs have been discontinued following efficacy or safety challenges, including bimagrumab, arimoclomol and sirolimus, substantially narrowing the development pipeline.</li><li>Ulviprubart is among the most advanced investigational IBM therapies and is being evaluated in a registrational Phase II/III clinical trial.</li><li>Current innovation is focused on targeted immunotherapies and muscle-protective strategies designed to slow disease progression and preserve physical function.</li></ul> Inclusion Body Myositis Disease and Diagnosis Overview Inclusion body myositis is a rare, progressive muscle disease that most commonly develops after age 50 and affects men more frequently than women. Its clinical presentation typically includes slowly progressive, asymmetric weakness involving the quadriceps and finger flexors. Patients may also experience recurrent falls, impaired mobility and dysphagia. Disease pathology involves inflammatory muscle injury and degenerative protein accumulation. IBM diagnosis is based on clinical presentation, laboratory testing, electromyography, muscle imaging and histopathological findings. Creatine kinase levels may be normal or mildly elevated, while electromyography can demonstrate myopathic and neurogenic changes. Muscle biopsy remains an important component of diagnostic confirmation, with findings that may include endomysial inflammation, rimmed vacuoles and abnormal protein aggregates. Inclusion Body Myositis Epidemiology The report evaluates historical and forecast IBM epidemiology across the 7MM by total prevalent cases, age and gender. Published estimates place prevalence at approximately five to nine cases per million adults, although rates vary according to geography, ethnicity, age and diagnostic practices. The United States is estimated to have approximately 20,000 to 25,000 IBM cases. IBM usually develops after age 50. Reported mean ages at symptom onset include 64.8 years for patients presenting with quadriceps weakness, 62.2 years for finger flexor weakness and 67.7 years for swallowing difficulties. The analysis examines how demographic trends, diagnostic awareness and regional differences may influence the diagnosed patient population through 2034. IBM Treatment Landscape and Unmet Medical Need No curative or FDA-approved pharmacological treatment is currently available for inclusion body myositis. Off-label immunosuppressive and immunomodulatory drugs have generally produced inconsistent outcomes, reinforcing the need for effective disease-modifying therapies. Current treatment practices prioritize mobility, independence, fall prevention and management of complications such as dysphagia. The IBM market has also been affected by clinical development setbacks. Bimagrumab did not demonstrate sufficient functional benefit, arimoclomol failed to meet key study endpoints, and sirolimus showed limited efficacy with substantial adverse effects in some patients. These discontinuations have reduced the number of viable late-stage candidates and increased the strategic importance of the remaining IBM pipeline. Emerging IBM Therapy: Ulviprubart Ulviprubart, also known as ABC008, is a first-in-class anti-KLRG1 antibody developed by Abcuro. The therapy is designed to selectively deplete highly cytotoxic T cells while preserving naive, regulatory and central memory T-cell populations. It is being evaluated in the Phase II/III MUSCLE clinical trial for inclusion body myositis. Abcuro completed enrollment in the registrational MUSCLE trial in June 2024. In March 2025, the company presented Phase I safety, pharmacokinetic and pharmacodynamic findings at the American Academy of Neurology Annual Meeting. Ulviprubart represents one of the most advanced targeted candidates in the IBM pipeline and could influence future treatment practices if clinical development is successful. Inclusion Body Myositis Market Outlook The inclusion body myositis market is expected to evolve as diagnostic awareness improves and targeted therapies advance. The report assesses historical and forecast market size, therapy-specific market share, competitive positioning and anticipated drug uptake from 2020 to 2034. Uptake forecasts consider clinical efficacy, safety, administration, market-entry timing, reimbursement and competition. The analysis also reviews pipeline development activities, including collaborations, licensing agreements, mergers and acquisitions, patent strategies and company-led research. Qualitative assessments incorporate SWOT and conjoint analyses to compare existing and emerging therapies based on efficacy, safety, tolerability, administration frequency, route of administration and expected launch sequence. Market Access, Reimbursement and Expert Insights The report examines country-specific market access and reimbursement conditions, health technology assessment requirements, cost-effectiveness and patient affordability. US coverage includes Medicare, Medicaid, the Children's Health Insurance Program, federal and state insurance marketplaces, private insurers and pharmacy benefit managers. Comparable access considerations are evaluated across Europe, the United Kingdom and Japan. Primary research incorporates perspectives from key opinion leaders and subject-matter experts across the 7MM. More than 15 experts were contacted, with over five interviews conducted to validate epidemiological assumptions, treatment patterns, unmet needs and market trends. Institutions approached included Washington University School of Medicine and University Medical Center Hamburg-Eppendorf. Report Scope and Strategic Value <ul><li>Historical and forecast inclusion body myositis epidemiology from 2020 to 2034</li><li>IBM market size and therapy-level market share across the 7MM</li><li>Current treatment practices, diagnostic pathways and unmet medical needs</li><li>Profiles of emerging IBM drugs and pipeline candidates</li><li>Drug uptake forecasts and competitive landscape analysis</li><li>Market access, reimbursement and cost-effectiveness insights</li><li>SWOT and conjoint analyses of current and investigational therapies</li><li>Expert perspectives on epidemiology, clinical practice and market development</li></ul> The report supports pharmaceutical companies, investors, healthcare organizations and other stakeholders seeking to understand the future of the inclusion body myositis market. Its findings can inform portfolio planning, clinical development, market-entry strategy, competitive intelligence, sales prioritization and partnership decisions across the United States, Europe and Japan. Key Topics Covered: 1. Key Insights 2. Report Introduction 3. Executive Summary of Inclusion Body Myositis (IBM) 4. Key Events 5. Inclusion Body Myositis (IBM) Epidemiology and Market Forecast Methodology 6. Inclusion Body Myositis (IBM) Market Overview at a Glance 6.1. Market Share (%) Distribution of Inclusion Body Myositis (IBM) by Therapies in 2024 6.2. Market Share (%) Distribution of Inclusion Body Myositis (IBM) by Therapies in 2034 7. Disease Background and Overview: Inclusion Body Myositis (IBM) 7.1. Introduction 7.2. Signs and Symptoms 7.3. Causes 7.4. Diagnosis 8. Treatment and Management 8.1. Treatment Guidelines and Recommendations 9. Epidemiology and Patient Population of Inclusion Body Myositis (IBM) in the 7MM 9.1. Key Findings 9.2. Assumptions and Rationale 9.3. Total Prevalent Cases of IBM in the 7MM 9.4. The United States 9.4.1. Total Prevalent Cases of IBM in the United States 9.4.2. Age-specific Cases of IBM in the United States 9.4.3. Gender-specific Cases of IBM in the United States 9.5. EU4 and the UK 9.5.1. Total Prevalent Cases of IBM in EU4 and the UK 9.5.2. Age-specific Cases of IBM in EU4 and the UK 9.5.3. Gender-specific Cases of IBM in EU4 and the UK 9.6. Japan 9.6.1. Total Prevalent Cases of IBM in Japan 9.6.2. Age-specific Cases of IBM in Japan 9.6.3. Gender-specific Cases of IBM in Japan 10. Patient Journey 11. Emerging Therapies 11.1. Key Competitors 11.2. Ulviprubart (ABC008): Abcuro 11.2.1. Product Description 11.2.2. Other Developmental Activity 11.2.3. Clinical Developmental Activities 11.2.4. Safety and efficacy 11.2.5. Analyst Views List to be continued in the report. 12. Inclusion Body Myositis (IBM): Seven Major Market Analysis 12.1. Key Findings 12.2. Key Market Forecast Assumptions 12.2.1. Cost Assumptions and Rebate 12.2.2. Pricing Trends 12.2.3. Analogue Assessment 12.2.4. Launch Year and Therapy Uptake 12.3. Market Outlook 12.4. Total Market Size of IBM in the 7MM 12.5. United States Market Size 12.5.1. Total Market Size of IBM in the United States 12.5.2. Market Size of IBM by Therapies in the United States 12.6. EU4 and the UK Market Size 12.6.1. Total Market Size of IBM in the EU4 and the UK 12.6.2. Market size of IBM by Therapies in the EU4 and the UK 12.7. Japan Market Size 12.7.1. Total Market Size of IBM in Japan 12.7.2. Market Size of IBM by Therapies in Japan 13. Unmet Needs 14. SWOT Analysis 15. KOL Views 16. Market Access and Reimbursement 17. Appendix 17.1. Bibliography 17.2. Report Methodology 18. Publisher Capabilities 19. Disclaimer 20. About the Publisher List of Tables Table 1: 7MM Inclusion Body Myositis Epidemiology (2020-2034) Table 2: 7MM Inclusion Body Myositis Diagnosed and Treatable Cases (2020-2034) Table 3: Inclusion Body Myositis Epidemiology in the United States (2020-2034) Table 4: Inclusion Body Myositis Diagnosed and Treatable Cases in the United States (2020-2034) Table 5: Inclusion Body Myositis Epidemiology in Germany (2020-2034) Table 6: Inclusion Body Myositis Diagnosed and Treatable Cases in Germany (2020-2034) Table 7: Inclusion Body Myositis Epidemiology in France (2020-2034) Table 8: Inclusion Body Myositis Diagnosed and Treatable Cases in France (2020-2034) Table 9: Inclusion Body Myositis Epidemiology in Italy (2020-2034) Table 10: Inclusion Body Myositis Diagnosed and Treatable Cases in Italy (2020-2034) Table 11: Inclusion Body Myositis Epidemiology in Spain (2020-2034) Table 12: Inclusion Body Myositis Diagnosed and Treatable Cases in Spain (2020-2034) Table 13: Inclusion Body Myositis Epidemiology in the UK (2020-2034) Table 14: Inclusion Body Myositis Diagnosed and Treatable Cases in the UK (2020-2034) Table 15: Inclusion Body Myositis Epidemiology in Japan (2020-2034) Table 16: Inclusion Body Myositis Diagnosed and Treatable Cases in Japan (2020-2034) Table 17: Drug Name, Clinical Trials by Recruitment status Table 18: Drug Name, Clinical Trials by Zone Table 19: Total Seven Major Market Size in USD, Million (2020-2034) Table 20: Region-wise Market Size in USD, Million (2020-2034) Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034) Table 22: United States Market Size in USD, Million (2020-2034) Table 23: United States Market Size by Therapy in USD, Million (2020-2034) Table 24: Germany Market Size in USD, Million (2020-2034) Table 25: Germany Market Size by Therapy in USD, Million (2020-2034) Table 26: France Market Size in USD, Million (2020-2034) Table 27: France Market Size by Therapy in USD, Million (2020-2034) Table 28: Italy Market Size in USD, Million (2020-2034) Table 29: Italy Market Size by Therapy in USD, Million (2020-2034) Table 30: Spain Market Size in USD, Million (2020-2034) Table 31: Spain Market Size by Therapy in USD, Million (2020-2034) Table 32: United Kingdom Market Size in USD, Million (2020-2034) Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034) Table 34: Japan Market Size in USD, Million (2020-2034) Table 35: Japan Market Size by Therapy in USD, Million (2020-2034) List of Figures Figure 1: 7MM Inclusion Body Myositis Epidemiology (2020-2034) Figure 2: 7MM Inclusion Body Myositis Diagnosed and Treatable Cases (2020-2034) Figure 3: Inclusion Body Myositis Epidemiology in the United States (2020-2034) Figure 4: Inclusion Body Myositis Diagnosed and Treatable Cases in the United States (2020-2034) Figure 5: Inclusion Body Myositis Epidemiology in Germany (2020-2034) Figure 6: Inclusion Body Myositis Diagnosed and Treatable Cases in Germany (2020-2034) Figure 7: Inclusion Body Myositis Epidemiology in France (2020-2034) Figure 8: Inclusion Body Myositis Diagnosed and Treatable Cases in France (2020-2034) Figure 9: Inclusion Body Myositis Epidemiology in Italy (2020-2034) Figure 10: Inclusion Body Myositis Diagnosed and Treatable Cases in Italy (2020-2034) Figure 11: Inclusion Body Myositis Epidemiology in Spain (2020-2034) Figure 12: Inclusion Body Myositis Diagnosed and Treatable Cases in Spain (2020-2034) Figure 13: Inclusion Body Myositis Epidemiology in the UK (2020-2034) Figure 14: Inclusion Body Myositis Diagnosed and Treatable Cases in the UK (2020-2034) Figure 15: Inclusion Body Myositis Epidemiology in Japan (2020-2034) Figure 16: Inclusion Body Myositis Diagnosed and Treatable Cases in Japan (2020-2034) Figure 17: Drug Name, Clinical Trials by Recruitment status Figure 18: Drug Name, Clinical Trials by Zone Figure 19: Total Seven Major Market Size in USD, Million (2020-2034) Figure 20: Region-wise Market Size in USD, Million (2020-2034) Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034) Figure 22: United States Market Size in USD, Million (2020-2034) Figure 23: United States Market Size by Therapy in USD, Million (2020-2034) Figure 24: Germany Market Size in USD, Million (2020-2034) Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034) Figure 26: France Market Size in USD, Million (2020-2034) Figure 27: France Market Size by Therapy in USD, Million (2020-2034) Figure 28: Italy Market Size in USD, Million (2020-2034) Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034) Figure 30: Spain Market Size in USD, Million (2020-2034) Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034) Figure 32: United Kingdom Market Size in USD, Million (2020-2034) Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034) Figure 34: Japan Market Size in USD, Million (2020-2034) Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034) A selection of companies mentioned in this report includes, but is not limited to: <ul><li>Abcuro</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/report/global-inclusion-body-myositis-drug-market?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=cv7wbr&amp;utm_campaign=2325560+-+Inclusion+Body+Myositis+Market+Report+2020-2034%3a+Epidemiology%2c+Treatment+Landscape%2c+Pipeline+and+Forecast+Across+the+7M&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/2kloz5</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/MDg0ODJlN2EtOTYwMC00M2Q4LTg3MDAtNjI4NDYxNTkxMzNhLTEwMjY3MzctMjAyNi0wOC0xNC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Inclusion Body Myositis Market Report 2020-2034: Epidemiology, Treatment Landscape, Pipeline and Forecast Across the 7M

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn